Enanta Pharmaceuticals


Biopharmaceutical company focused on discovery and development of differentiated therapeutics using small-molecule medicinal chemistry and oligonucleotide approaches. The company has a history of developing antiviral combination regimens (including hepatitis C programs) that have reached patient-impacting outcomes, and maintains active pipelines in virology and immunology while operating programs for clinical development, partnerships, and corporate governance.

Industries

Biotechnology
Health Care
Pharmaceutical
Biotech & Pharmaceuticals
Pharmaceutical and biotechnology
Biotechnology Research

Nr. of Employees

medium (51-250)

Enanta Pharmaceuticals

Watertown, Massachusetts, United States


Patents

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

US-12753204-B2

View Details

Processes for the preparation of substituted spirooxindole derivatives

US-12747248-B2

View Details

Spiropyrrolidine derived antiviral agents

US-12643905-B2

View Details

Antiviral heterocyclic compounds

US-12612412-B2

View Details

Crystal forms of an anti-sars CoV-2 agent

US-12570663-B2

View Details

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

US-12552777-B2

View Details
View All Patents

Products

Antiviral programs — Hepatitis C virus (HCV)

Historic discovery and development contributions to hepatitis C therapeutic regimens that have achieved curative outcomes for patients.

Antiviral programs — Respiratory syncytial virus (RSV)

Development of oral small-molecule inhibitors in a respiratory virus program.

Antiviral programs — Hepatitis B virus (HBV)

Discovery and development activities targeting hepatitis B virus.

Antiviral programs — SARS-CoV-2 / COVID-19

Programs focused on SARS-CoV-2 therapeutic discovery.

Immunology programs — KIT, STAT6 and MRGPRX2 pathways

Discovery efforts targeting immunology pathways, including KIT inhibition, STAT6 inhibition and MRGPRX2 modulation for immune-mediated diseases.


Services

Engagement in strategic collaborations, licensing and co-development agreements to advance therapeutic programs.

Expertise Areas

  • Antiviral drug discovery
  • Small-molecule medicinal chemistry
  • Oligonucleotide (microRNA) therapeutics
  • Clinical trial management
  • Show More (4)

Key Technologies

  • Small-molecule inhibitor discovery
  • Oligonucleotide / microRNA therapeutics
  • Target-based virology (N-protein and other viral targets)
  • Preclinical virology assays
  • Show More (2)

News & Updates

Company to present data for an oral once-daily N-protein inhibitor in development for treatment of respiratory syncytial virus.

Company participation in investor conferences in September.

Financial results announcement for the fiscal third quarter ended June 30, 2026.

Discovery and development contributions to combination hepatitis C therapies that have cured more than one million patients.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.